Comparison of the effects of pioglitazone and voglibose on circulating total and high‐molecular‐weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes

Aso, Yoshimasa; Yamamoto, Ruriko; Suetsugu, Mariko; Matsumoto, Sachiko; Wakabayashi, Shigeo; Matsutomo, Rika; Takebayashi, Kohzo; Iwamoto, Toshihiko

doi:10.1111/j.1464-5491.2007.02204.x

Cited by 23 publications

(16 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings were at variance with another study which showed that pioglitazone did not reduce significantly plasma PAI-1 levels, despite elevations in adiponectin, 28 although a trend of reduction was apparent. It should be noted that the previous study involved half our sample size and treatment duration, and a relatively lower treatment dose, and the authors conceded that the baseline PAI-1 levels of their patients may not be high enough to accurately assess the lowering effect of pioglitazone.…”

Section: Discussioncontrasting

confidence: 57%

Adiponectin Mediates the Suppressive Effect of Rosiglitazone on Plasminogen Activator Inhibitor-1 Production

Hoo

Chow

Yau

et al. 2007

ATVB

View full text Add to dashboard Cite

Objective-The purpose of this study was to examine the effects of PPAR-␥ agonist rosiglitazone, relative to sulfonylureas, on circulating levels of adiponectin and the prothrombotic factor, plasminogen activator inhibitor (PAI)-1, in type 2 diabetic patients, and to investigate, in animal models, whether the antithrombotic action of rosiglitazone was mediated through adiponectin. Methods and Results-Our clinical study (nϭ64) showed that after 24-week add-on therapy, the rosiglitazone group had a greater mean reduction in plasma PAI-1 levels (25%, versus 12% in sulfonylurea group, Pϭ0.002).Stepwise multiple linear regression analysis identified the reduction in plasma fasting glucose and the rise in adiponectin levels to be independently associated with the reduction in PAI-I concentration in the rosiglitazone-treated patients. Rosiglitazone (20 mg/kg/d) reduced adipose tissue PAI-1 mRNA expression and its plasma levels in wild-type C57 mice with diet-induced obesity (PϽ0.001), but this suppressive effect was attenuated in adiponectin knockout mice. Adenovirusmediated overexpression of adiponectin led to a significant suppression of adipose tissue PAI-1 expression and its circulating concentrations in db/db diabetic mice. Our in vitro study demonstrated that recombinant adiponectin directly inhibited PAI-1 production in 3T3-L1 adipocytes. Conclusions-The

show abstract

Section: Discussioncontrasting

confidence: 57%

Adiponectin Mediates the Suppressive Effect of Rosiglitazone on Plasminogen Activator Inhibitor-1 Production

Hoo

Chow

Yau

et al. 2007

ATVB

View full text Add to dashboard Cite

show abstract

“…We also excluded patients with renal dysfunction (serum creatinine concentration >1.3 mg/dL) or liver dysfunction. Patients receiving treatment with peroxisome proliferatoractivated receptor (PPAR)-γ agonists, which increase the serum HMW adiponectin level, were also excluded (31).…”

Section: Methodsmentioning

confidence: 99%

Determinants of Serum High Molecular Weight (HMW) Adiponectin Levels in Patients with Coronary Artery Disease: Associations with Cardio-renal-anemia Syndrome

et al. 2011

View full text Add to dashboard Cite

Objective A low serum adiponectin level is associated with a high incidence of coronary artery disease (CAD) in the healthy population. Paradoxically, serum adiponectin is elevated in patients with severe CAD or chronic heart failure. We investigated the determinants of serum high molecular weight (HMW) adiponectin in patients with CAD. Patients and MethodsWe studied 228 consecutive patients with CAD confirmed by angiography. Anemia was defined as a hemoglobin of <13.0 g/dL in men and<12.0 g/dL in women. A high plasma B-type natriuretic-peptide (BNP) was defined as >100 pg/mL. Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate (eGFR) of <60 mL/min for more than 3 months. The patients with CAD were divided into eight groups according to the presence or absence of anemia, high BNP, and/or CKD. Results In all 228 patients with CAD, serum HMW adiponectin correlated positively with age, highdensity-lipoprotein cholesterol (HDL-C), and BNP, while this parameter showed negative correlations with body mass index, insulin resistance, triglycerides, eGFR, and hemoglobin. Multivariate analysis showed that HDL-C, BNP, gender, and age were independently associated with the HMW adiponectin. Serum HMW adiponectin was lower in CAD patients with than without metabolic syndrome. Serum HMW adiponectin and the HMW/total adiponectin ratio were highest in CAD patients who had anemia, high BNP, and CKD among the groups. Conclusion In patients with CAD, metabolic syndrome is associated with a lower serum HMW adiponectin, while the presence of anemia, high BNP, and CKD is associated with elevation of the serum HMW adiponectin.

show abstract

“…Co r r e l a t i o n b e t we e n S e r u m HMW ADP N L e v e l s a n d Cl i n i c a l P a r (25). It is noteworthy that serum ADPN levels are increased in type 1 diabetes patients (26).…”

Section: T a B L E 3 Co Mp A R I S O N O F Cl I N I C A L A N D B Imentioning

confidence: 99%

Relationship of High-Molecular-Weight Adiponectin Levels to Visceral Fat Accumulation in Hemodialysis Patients

et al. 2010

View full text Add to dashboard Cite

show abstract

Comparison of the effects of pioglitazone and voglibose on circulating total and high‐molecular‐weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes

Abstract: Increased serum HMW adiponectin may contribute to the improvement in glycaemic control after pioglitazone treatment. Plasma PAI-1 and TAFI were unchanged by either drug.

Cited by 23 publications

References 36 publications

Adiponectin Mediates the Suppressive Effect of Rosiglitazone on Plasminogen Activator Inhibitor-1 Production

Adiponectin Mediates the Suppressive Effect of Rosiglitazone on Plasminogen Activator Inhibitor-1 Production

Determinants of Serum High Molecular Weight (HMW) Adiponectin Levels in Patients with Coronary Artery Disease: Associations with Cardio-renal-anemia Syndrome

Relationship of High-Molecular-Weight Adiponectin Levels to Visceral Fat Accumulation in Hemodialysis Patients

Contact Info

Product

Resources

About